Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer — Webinar Video Proceedings

Faculty

TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, surgeons and other allied healthcare professionals involved in the treatment of lung cancer.

LEARNING OBJECTIVES

• Consider emerging research information and available guideline recommendations to individualize first- and later-line therapy for patients with non-small cell lung cancer (NSCLC) harboring various targetable genomic abnormalities beyond EGFR.
• Communicate the efficacy and safety of approved and investigational ALK inhibitors to patients with localized and metastatic NSCLC for whom treatment with these agents would be appropriate.
• Convey the clinical relevance of a positive ROS1 mutation testing result to applicable patients with NSCLC, and appreciate available research findings with approved and investigational agents demonstrating efficacy in this disease subtype.
• Assess available research evidence with approved RET inhibitors, and use this information to guide clinical care for patients with newly diagnosed or progressive NSCLC.
• Consider available research information and guideline recommendations to individualize first- and later-line therapy for patients with HER2-mutant or overexpressing NSCLC.
• Understand the biology of KRAS G12C mutations, and evaluate available research findings to optimally incorporate available agents into the care of patients with these abnormalities.
• Reflect on investigational agents and strategies currently in testing for NSCLC with targetable genomic abnormalities beyond EGFR, and refer eligible patients for clinical trial participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

AMERICAN BOARD OF SURGERY (ABS) — CONTINUOUS CERTIFICATION (CC)
Successful completion of these CME activities, which includes participation in the evaluation component and a post-test, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, these programs have been specifically designed for the following ABS practice area: complex general surgical oncology..

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS CME ACTIVITY
Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/YiR2024/TargetedLung/Video/CME.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Jessica J Lin, MD
Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committees: Bristol Myers Squibb, Genentech, a member of the Roche Group, Nuvalent; Consulting Agreements: AnHeart Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, CLaiM Therapeutics, Daiichi Sankyo Inc, Elevation Oncology, Ellipses Pharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Lilly, Merus, Mirati Therapeutics Inc, Novartis, Nuvalent, Nuvation Bio, Pfizer Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc, Yuhan USA; Contracted Research (Received Institutional Research Funds): Bayer HealthCare Pharmaceuticals, BioNTech SE, Elevation Oncology, Hengrui Therapeutics Inc, Linnaeus Therapeutics, Novartis, Nuvalent, Relay Therapeutics, Roche Laboratories Inc, Turning Point Therapeutics Inc; Travel Support: Bristol Myers Squibb, Merus, Pfizer Inc, Takeda Pharmaceuticals USA Inc.

Joel W Neal, MD, PhD
Professor of Medicine, Division of Oncology
Stanford University School of Medicine
Medical Director, Cancer Clinical Trials Office
Stanford Cancer Institute
Medical Director, Informatics Technology
Stanford Medicine Cancer Center
Stanford, California

Advisory Committees (Consulting or Advisory Roles): AbbVie Inc, Amgen Inc, AnHeart Therapeutics, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, D2G Oncology Inc, Daiichi Sankyo Inc, Exelixis Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Iovance Biotherapeutics, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Natera Inc, Novartis, Novocure Inc, Nuvation Bio, Regeneron Pharmaceuticals Inc, Sanofi, Summit Therapeutics, Surface Oncology, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc; Contracted Research: Adaptimmune, Boehringer Ingelheim Pharmaceuticals Inc, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Merck, Nektar Therapeutics, Novartis, Nuvalent, Revolution Medicines, Takeda Pharmaceuticals USA Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, and Nuvalent.

Release date: June 2025
Expiration date: June 2026

After completing the post-test, learners may download and review the answers here in order to identify further areas of study.

Bauer T et al. Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. WCLC 2024;Abstract MA06.08.

Besse B et al. Phase I/II ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumours. ESMO 2024;Abstract 1256MO.

Camidge DR et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol 2024;42(25):3000-11. Abstract

Cho BC et al. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer. Lung Cancer 2024;188:107442. Abstract

Drilon AE at al. Phase I/II ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumours. ESMO 2024;Abstract 1253O.

Drilon AE et al. Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies. ASCO 2024;Abstract 8522.

Fujiwara Y et al. Efficacy and safety of olomorasib with pembrolizumab + chemotherapy as first-line treatment in patients with KRAS G12C-mutant advanced NSCLC. WCLC 2024;Abstract OA14.04.

Heymach JV et al. Zongertinib in previously treated HER2-mutant non–small-cell lung cancer. N Engl J Med 2025;[Online ahead of print]. Abstract

Hill L et al. Predictors of long-term ensartinib response from the eXalt3 trial. WCLC 2024;Abstract MA06.09.

Horinouchi H et al. ALINA safety results; adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC). WCLC 2024;Abstract OA13.04.

Janne PA et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. ASCO 2024;Abstract 8543.

Le X et al. Safety and efficacy of BAY 2927088 in patients with HER2-mutant NSCLC: Expansion cohort from the phase I/II SOHO-01 study. WCLC 2024;Abstract PL04.03.

Lin JJ et al. Updated efficacy, safety, and biomarker analysis in patients with TRK fusion lung cancer treated with larotrectinib. WCLC 2024;Abstract MA06.12.

Liu G et al. Efficacy and safety of taletrectinib in patients with ROS1+ non-small cell lung cancer: The global TRUST-II study. WCLC 2024;Abstract MA06.03.

Mok TSK et al. KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation. ASCO 2024;Abstract LBA8509.

Nützinger J et al. Management of HER2 alterations in non-small cell lung cancer – The past, present, and future. Lung Cancer 2023;186:107385. Abstract

Pérol M et al. CNS protective effect of selpercatinib in first-line RET fusion-positive advanced non-small cell lung cancer. J Clin Oncol 2024;42(21):2500-5. Abstract

Planchard D et al. Trastuzumab deruxtecan monotherapy in pretreated HER2-overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1. WCLC 2024;Abstract OA16.05.

Riely GJ et al. Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). ESMO 2024;Abstract LBA56.

Ruiter G et al. Primary phase Ib analysis of Beamion LUNG-1: Zongertinib (BI 1810631) in patients with HER2 mutation-positive NSCLC. WCLC 2024;Abstract PL04.04.

Sacher A et al. Divarasib single-agent long-term follow-up and atezolizumab combination treatment in patients with KRAS G12C-positive NSCLC. WCLC 2024;Abstract OA14.06.

Sands J et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: Results from the phase II TROPION-Lung05 study. J Clin Oncol 2025;43(10):1254-65. Abstract

Schram AM et al. Efficacy of zenocutuzumab in NRG1 fusion-positive cancer. N Engl J Med 2025;392(6):566-76. Abstract

Smit EF et al. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol 2024;25(4):439-54. Abstract

Solomon BJ et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol 2024;42(29):3400-9. Abstract

Waterhouse DM et al. Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation. Lung Cancer 2024;196:107921. Abstract

Wolf J et al. Capmatinib in MET exon 14-Mutated non-small-cell lung cancer: Final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol 2024;25(10):1357-70. Abstract

Wu Y-L et al. Alectinib in resected ALK-positive non-small-cell lung cancer. N Engl J Med 2024;390(14):1265-76. Abstract